|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3730 USD | -0.45% |
|
-1.87% | -88.71% |
| Nov. 06 | VYNE Therapeutics Q3 net loss narrows, strategic review ongoing | RE |
| Nov. 06 | VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 | CI |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | $4 | +967.52% | 2 | ||||||
| €762.98 | -4.51% | 13 | ||||||
| $220.41 | +6.59% | 17 | ||||||
| CN¥125.98 | +43.78% | 19 | ||||||
| $118.04 | +42.34% | 19 | ||||||
| DKK 2,054.66 | +1.56% | 14 | ||||||
| HK$35.85 | +28.13% | 25 | ||||||
| HK$155.27 | +44.59% | 21 | ||||||
| $24.26 | +74.63% | 13 | ||||||
| HK$535.62 | +23.99% | 17 | ||||||
| $563.8 | -2.77% | 15 | ||||||
| $44.94 | +2.12% | 18 | ||||||
| $141.82 | +32.67% | 17 | ||||||
| $57.67 | -11.38% | 12 | ||||||
| $79.56 | +23.04% | 18 | ||||||
| ₩124,500 | -38.06% | 6 | ||||||
| - | - | - | - | - | ||||
| Average | 8,089.05 | +77.14% | 15 | ||||||
| Weighted average by Cap. | 3,594.7 | +17.50% | 16 |
- Stock Market
- Equities
- VYNE Stock
- Sector VYNE Therapeutics Inc.
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
